Boston Scientific Q1 2020 Earnings Report
Key Takeaways
Boston Scientific's Q1 2020 sales reached $2.543 billion, reflecting growth on a reported and operational basis, but a decline on an organic basis. GAAP earnings per share decreased, while adjusted earnings per share also saw a reduction compared to the prior year. The company withdrew its Q1 2020 sales and EPS guidance due to the COVID-19 pandemic.
Sales grew by 2.0% on a reported basis, 3.2% on an operational basis, but declined 2.9% organically.
GAAP earnings were $0.01 per share, down from $0.30 per share in the previous year.
Adjusted earnings per share were $0.28, compared to $0.35 a year ago.
The company withdrew its Q1 2020 sales and EPS guidance due to the uncertain impact of the COVID-19 pandemic.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Forward Guidance
Due to the uncertain scope and duration of the COVID-19 pandemic, the company withdrew its full-year 2020 sales and EPS guidance.
Challenges Ahead
- Uncertain scope and duration of the COVID-19 pandemic.
- Uncertainty regarding the timing of global recovery.
- Inability to estimate the overall impacts on operations.
- Inability to estimate the impacts on financial results.
- Withdrawal of full-year 2020 sales and EPS guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income